| HOME >> BIOLOGY >> TECHNOLOGY |
Bladder Cancer Therapeutics by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed by
Annual Revenues in US$ Million for the Years 2007 through 2015
(includes corresponding Graph/Chart) II-69
Table 11: World Historic Review for Bladder Cancer
Therapeutics by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed by Annual
Revenues in US$ Million for the Years 2001 through 2006
(includes corresponding Graph/Chart) II-70
Table 12: World 11-Year Perspective for Bladder Cancer
Therapeutics by Geographic Region - Percentage Breakdown of
Revenues for US, Japan, Europe, and Rest of World Markets for
the Years 2005, 2010 & 2015 (includes corresponding
Graph/Chart) II-71
III. MARKET
1. UNITED STATES III-1
A.Market Analysis III-1
Bladder Cancer & Prevalence - A Recapitulation of Facts III-1
Mortality Rates Higher in African Americans III-2
Table 13: Incidence of Bladder Cancer Among African
Americans (Males): Percentage Share Breakdown by Select
Cancer/Type or Site and Gender for the Year 2007 (includes
corresponding Graph/Chart) III-2
Bladder Cancer - A Costly Urologic Condition III-3
Table 14: Urologic Disease Costs in the US: 2006 (includes
corresponding Graph/Chart) III-3
US Bladder Cancer Statistics III-3
Table 15: Bladder Cancer Prevalence and Mortality in the US
by Gender: Percentage Share Breakdown for 2009 III-3
Table 16: Bladder Cancer Incidence in the US by Gender:
Percentage Share Breakdown for 2008 III-3
FDA Approval III-4
Strategic Corporate Developments III-6
Select Players III-12
Allergan, Inc. III-12
Allos Therapeutics, Inc. III-13
AVI BioPharma, Inc. III-13
Bristol-Myers Squibb Company III-14
<| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |